An observational study in Inherited Movement Disorders, Spinocerebellar Ataxias and Hyperkinetic Disorders, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 7 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-12.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Spinocerebellar Ataxias with a site in France — 5 open to participants now, 7 under way, none of them phase 3. Spinocerebellar Ataxias · France.
Among the 13 studies in Spinocerebellar Ataxias with a site in France, this one is the only one that started in 2021, is one of 7 observational ones, and was the 8th registered.
95 studies on the registry are indexed under Spinocerebellar Ataxias; 25 are open to participants now.
Browse Spinocerebellar Ataxias studies →5 of the 13 studies in Spinocerebellar Ataxias with a site in France are open now. Recruiting first, the newest first:
University Hospital, Angers · Sites in France
Ages 18–100 · Healthy volunteers
University Hospital, Montpellier · Sites in France
Ages 18–80
Vico Therapeutics B. V. · Sites in France, Denmark, Germany and 3 more countries
Ages 25–60
Ataxia Study Group · Sites in France, Austria, Belgium and 7 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 16 Spinocerebellar Ataxias studies recruiting now, 8 (50%) set no upper age limit and 3 (19%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 7 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 1
First in 2005; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,000 is above the median of 128 across 25 observational studies indexed under Spinocerebellar Ataxias.
Median enrollment 60 across the 6 interventional studies, 102 across the 7 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 8 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 3 studies filed under Spinocerebellar Ataxias — fewer than ten, so there is no comparison to draw.
2 of the studies in Spinocerebellar Ataxias with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672445Arrowhead PharmaceuticalsStudy of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 | 2026-12 |
| NCT07019558University Hospital, MontpellierOphthalmological Disorders in Dominant Spinal-cerebellar Ataxias | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Spinocerebellar Ataxias with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Inherited movement disorders are rare conditions, whose cumulative prevalence are in the order of 5-10/100,000 inhabitants, in most cases progressive and can lead to a significant loss of autonomy after one or more decades of evolution. They include spinocerebellar ataxias and hyperkinetic disorders (dystonias, choreas, tremor, parkinsonism and myoclonus with variable combination of those, or more complex alteration of movements). The existence of the National Reference Centre (CMR) for Rare Diseases (CMR Neurogenetics, devoted to ataxias and spastic paraparesis, dystonia and rare movement disorders and CMR Huntington, devoted to Huntington Disease) has allowed a more integrated vision of these diseases. This is illustrated, in the same family, by the occurrence of different clinical expressions of spinocerebellar ataxias and hyperkinetic disorders that share the same genetic background. Conversely, different causal mutations within the same gene may have very different ages at onset and a wide range of clinical expression, and the spectrum of new phenotypes linked to a single gene is still expanding . Many ataxia and dystonia genes are involved in similar pathways. There are numerous arguments supporting a share pathogenesis including synaptic transmission and neurodevelopment .
BIOMOV project aims to :
Inherited movement disorders are rare conditions, whose cumulative prevalence are in the order of 5-10/100,000 inhabitants, in most cases progressive and can lead to a significant loss of autonomy after one or more decades of evolution. They include spinocerebellar ataxias and hyperkinetic disorders (dystonias, choreas, tremor, parkinsonism and myoclonus with variable combination of those, or more complex alteration of movements). The existence of the National Reference Centre (CMR) for Rare Diseases (CMR Neurogenetics, devoted to ataxias and spastic paraparesis, dystonia and rare movement disorders and CMR Huntington, devoted to Huntington Disease) has allowed a more integrated vision of these diseases. This is illustrated, in the same family, by the occurrence of different clinical expressions of spinocerebellar ataxias and hyperkinetic disorders that share the same genetic background. Conversely, different causal mutations within the same gene may have very different ages at onset and a wide range of clinical expression, and the spectrum of new phenotypes linked to a single gene is still expanding .
any ataxia and dystonia genes are involved in similar pathways. There are numerous arguments supporting a share pathogenesis including synaptic transmission and neurodevelopment .
Overall, there are a number of arguments for a shared genetic approach and biomarkers research for these inherited movement disorders:
These elements demonstrate the need to develop quantitative tools that are easy to use, reproducible and sensitive to disease progression in order to accurately determine the natural history of the disease. This lack of systematic knowledge impedes diagnosis, patient counselling and therapy development.
Overall: Identification of the underlying gene and its pathogenic changes or variant(s) contributes to precise diagnosis, genetic counselling and follow-up. Advances in molecular genetics have highlighted the genotypic complexity, justifying the need for rigorous clinical and para-clinical evaluation to establish relevant phenotype-genotype correlations. In dystonia and in spinocerebellar degenerations attempts have been made to classify the genes involved.
Molecular genetic analysis will make it possible to specify the correlations between phenotype and genotype in order to propose rational molecular diagnostic strategies based on the frequency and nature of mutations, taking into account the phenotype. Genetic analyses will have an impact in terms of public health since they will serve as a basis for guiding requests for molecular analyses in these pathologies. In addition, recent advances in therapeutic trials will need the careful selection of participants, mostly based on biomarkers, for successful testing of new therapeutical agents. Therefore, it seems essential that this cohort of patients be supplemented by a collection of biological material for genetic research.
BIOMOV project aims to : 1) establish the clinical spectrum and natural history of these diseases, 2) understand the role of genetic and familial factors on the phenotype, 3) elucidate the molecular basis of these disorders and evaluate diagnostic strategies involving molecular tools for clinical and genetic management, 4) develop multimodal biomarkers both for physiopathological studies and for accurate measures of disease progression, 5) develop trial ready cohorts of well characterized genetic patients, 6) test new therapies either symptomatic or based on pathophysiological mechanisms.
It is crucial to be able to establish a large cohort of patients whose genotype will be specified. Follow-up of patients at different stages of the disease will make it possible to collect the natural history of the disease in a descriptive manner, with prospects for patient management, since the prognosis in terms of loss of autonomy or disability will be better specified. However, the main interest of the proposed clinical follow-up is to be able to quantitatively describe the progression of the main neurological diseases. These data are absolutely essential for the future implementation of therapeutic trials. The number of patients likely to be recruited and followed up a unique resource for such a project
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Common inclusion criteria for all participants:
Group of patients:
Any patient with inherited hyperkinetic movement disorders can be included in the study according to the following criteria:
Woman or man;
Group of at-risk individuals:
Group of healthy controls:
Common inclusion criteria for elective participant for skin (optional): - Age ≥10 ans
Common inclusion criteria for elective participant for MRI examination (optional): - Ability to undergo a MRI.
Exclusion Criteria:
Absolute criteria for non-inclusion for all groups:
to MRI examination* (optional): metallic implant, pacemaker, artificial heart valve, brain vascular malformation, aneurysm clips, exposed by metallic fragments, artificial implants, peripheral or neuronal stimulator, insulin pump, intravenous catheter, epilepsy, metallic device, claustrophobia,
Contra-indication to skin (optional):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinical Follow-up: demographic data and history, * Retrospective interview (collection of data useful for genetic studies): -disease history (for patients only); * Family history - Neurological examination: * Diagnosis Clinical examination; * Rating scales specific to the pathology under investigation; * Cerebral MRI (optional) * Biological samples (optional)
Genetic entities among rare movement disorders: Pathology characterization (clinical spectrum) and its natural history: clinical Biomarkers
Comparison of clinical biomarkers at different disease stages compared to controls.
Time frame: 10 years
Genetic entities among rare movement disorders: Pathology characterization (clinical spectrum) and its natural history : genetic Biomarkers
Comparison of genetic biomarkers at different disease stages compared to controls.
Time frame: 10 years
Genetic entities among rare movement disorders: Pathology characterization (clinical spectrum) and its natural history : biological and/or imaging Biomarkers
Comparison of biological and/or imaging biomarkers at different disease stages compared to controls.
Time frame: 10 years
Started Aug 2021 (actual). Primary completion is estimated for Aug 2031, 120 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →